{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T21:52:36Z","timestamp":1781301156339,"version":"3.54.1"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T00:00:00Z","timestamp":1638230400000},"content-version":"vor","delay-in-days":260,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Diffuse large B-cell lymphoma (DLBCL) represents the most common subtype of non-Hodgkin lymphoma in the U.S., but current real-world data are limited. This study was conducted to describe real-world characteristics, treatment patterns, health care resource utilization (HRU), and health care costs of patients with treated DLBCL in the U.S.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>A retrospective study was conducted using the Optum Clinformatics Data Mart database (January 2013 to March 2018). Patients with an International Classification of Diseases, Tenth Revision, Clinical Modification diagnosis for DLBCL after October 2015 and no prior International Classification of Diseases, Ninth Revision, Clinical Modification diagnosis for unspecified DLBCL or primary mediastinal large B-cell lymphoma were classified as incident; those with such codes were classified as prevalent. An adapted algorithm identified lines of therapy (e.g., first line [1L]). All-cause HRU and costs were calculated per-patient-per-year (PPPY) among patients with a \u22651L.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 1,877 incident and 651 prevalent patients with \u22651L, median age was 72\u2009years and 46% were female. Among incident patients, 22.6% had at least two lines (2L), whereas 38.4% of prevalent patients had \u22652L. The most frequent 1L therapy was rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Incident patients had 1.3 inpatient and 42.0 outpatient (OP) visits PPPY, whereas prevalent patients had 0.8 and 31.3 visits PPPY, respectively. Total costs were $137,156 and $81,669 PPPY for incident and prevalent patients, respectively. OP costs were the main driver of total costs at $88,202 PPPY, which were higher within the first year.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This study showed that a large portion of patients require additional therapy after 1L treatment to manage DLBCL and highlighted the substantial economic burden of patients with DLBCL, particularly within the first year following diagnosis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Implications for Practice<\/jats:title>\n                  <jats:p>Patients diagnosed with diffuse large B-cell lymphoma (DLBCL) carry a substantial clinical and economic burden. A large portion of these patients require additional therapy beyond first-line treatment. There is significant unmet need among patients with DLBCL who require additional therapy beyond first-line treatment. Patients who do not respond to first-line therapy and are not eligible for transplants have very high health care resource utilization and costs, especially in the first 12 months following initiation of treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1002\/onco.13721","type":"journal-article","created":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T11:50:10Z","timestamp":1613994610000},"page":"e817-e826","source":"Crossref","is-referenced-by-count":24,"title":["Real-World Characteristics, Treatment Patterns, Health Care Resource Use, and Costs of Patients with Diffuse Large B-Cell Lymphoma in the U.S"],"prefix":"10.1093","volume":"26","author":[{"given":"Xiaoqin","family":"Yang","sequence":"first","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Lalibert\u00e9","sequence":"additional","affiliation":[{"name":"Groupe d'analyse, Lt\u00e9e, Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Germain","sequence":"additional","affiliation":[{"name":"Groupe d'analyse, Lt\u00e9e, Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Raut","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei Sheng","family":"Duh","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuvayu S.","family":"Sen","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Lejeune","sequence":"additional","affiliation":[{"name":"Groupe d'analyse, Lt\u00e9e, Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaushal","family":"Desai","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Armand","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,3,15]]},"reference":[{"key":"2021122511445281400_onco13721-bib-0001","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ajh.25460","article-title":"Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment","volume":"94","author":"Liu","year":"2019","journal-title":"Am J Hematol"},{"key":"2021122511445281400_onco13721-bib-0002","volume-title":"Types of B-cell Lymphoma. 2019","author":"American Cancer Society"},{"key":"2021122511445281400_onco13721-bib-0003","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3322\/caac.21357","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"2021122511445281400_onco13721-bib-0004","volume-title":"Cancer Stat Facts: NHL - Diffuse Large B-Cell Lymphoma (DLBCL). 2019","author":"National Cancer Institute (NCI) Surveillance E, and End Results Program (SEER)"},{"key":"2021122511445281400_onco13721-bib-0005","volume-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) - B-Cell Lymphomas","author":"National Comprehensive Cancer Network","year":"2019"},{"key":"2021122511445281400_onco13721-bib-0006","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: A study by the Groupe d'Etudes des Lymphomes de l'Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"key":"2021122511445281400_onco13721-bib-0007","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: Results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"2021122511445281400_onco13721-bib-0008","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin's lymphoma","volume":"329","author":"International Non-Hodgkin's Lymphoma Prognostic Factors Project","year":"1993","journal-title":"N Engl J Med"},{"key":"2021122511445281400_onco13721-bib-0009","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","article-title":"The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"109","author":"Sehn","year":"2007","journal-title":"Blood"},{"key":"2021122511445281400_onco13721-bib-0010","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1182\/asheducation-2016.1.366","article-title":"Diffuse large B-cell lymphoma: R-CHOP failure-what to do?","volume":"2016","author":"Coiffier","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2021122511445281400_onco13721-bib-0011","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1182\/asheducation-2011.1.498","article-title":"Relapsed\/refractory diffuse large B-cell lymphoma","volume":"2011","author":"Friedberg","year":"2011","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2021122511445281400_onco13721-bib-0012","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1634\/theoncologist.2018-0490","article-title":"Direct costs associated with relapsed diffuse large B-cell lymphoma therapies","volume":"24","author":"Purdum","year":"2019","journal-title":"The Oncologist"},{"key":"2021122511445281400_onco13721-bib-0013","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2217\/cer-2018-0094","article-title":"Economic burden and treatment patterns for patients with diffuse large B-cell lymphoma and follicular lymphoma in the USA","volume":"8","author":"Ren","year":"2019","journal-title":"J Comp Eff Res"},{"key":"2021122511445281400_onco13721-bib-0014","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2217\/fon-2018-0788","article-title":"Evaluation of treatment patterns and survival among patients with diffuse large B-cell lymphoma in the USA","volume":"15","author":"Morrison","year":"2019","journal-title":"Future Oncol"},{"key":"2021122511445281400_onco13721-bib-0015","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1179\/1607845414Y.0000000228","article-title":"Treatment patterns and outcomes among patients with high-intermediate\/high-risk diffuse large B-cell lymphoma in the USA","volume":"20","author":"Mytelka","year":"2015","journal-title":"Hematology"},{"key":"2021122511445281400_onco13721-bib-0016","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1080\/10428194.2016.1228924","article-title":"Second-line therapy in diffuse large B-cell lymphoma (DLBCL): Treatment patterns and outcomes in older patients receiving outpatient chemotherapy","volume":"58","author":"Danese","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"2021122511445281400_onco13721-bib-0017","volume-title":"World Health Organization Classification of Tumours","author":"WHO classification of tumours of haematopoietic lymphoid tissues","year":"2008","edition":"4th ed"},{"key":"2021122511445281400_onco13721-bib-0018","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"2021122511445281400_onco13721-bib-0019","volume-title":"World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Vol. 3: World Health Organization Press","author":"Jaffe","year":"2001"},{"key":"2021122511445281400_onco13721-bib-0020","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1634\/theoncologist.2014-0059","article-title":"Investigation of adverse-event-related costs for patients with metastatic breast cancer in a real-world setting","volume":"19","author":"Hurvitz","year":"2014","journal-title":"The Oncologist"},{"key":"2021122511445281400_onco13721-bib-0021","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2217\/lmt.15.12","article-title":"First-, second- and third-line lung cancer treatment patterns and associated costs in a US healthcare claims database","volume":"4","author":"Ramsey","year":"2015","journal-title":"Lung Cancer Management"},{"key":"2021122511445281400_onco13721-bib-0022","doi-asserted-by":"crossref","first-page":"461","DOI":"10.18553\/jmcp.2013.19.6.461","article-title":"Medical costs associated with use of systemic therapy in adults with colorectal cancer","volume":"19","author":"Seal","year":"2013","journal-title":"J Manag Care Pharm"},{"key":"2021122511445281400_onco13721-bib-0023","article-title":"Assessment of costs associated with adverse events in patients with cancer","volume":"13","author":"Wong","year":"2018","journal-title":"PLoS One"},{"key":"2021122511445281400_onco13721-bib-0024","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med"},{"key":"2021122511445281400_onco13721-bib-0025","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1182\/blood-2002-12-3837","article-title":"Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma","volume":"102","author":"Hamlin","year":"2003","journal-title":"Blood"},{"key":"2021122511445281400_onco13721-bib-0026","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw257","article-title":"Beyond RCHOP: A blueprint for diffuse large B cell lymphoma research","volume":"108","author":"Nowakowski","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"2021122511445281400_onco13721-bib-0027","doi-asserted-by":"crossref","DOI":"10.4155\/fsoa-2018-0049","article-title":"Systematic review of therapy used in relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma","volume":"4","author":"Galaznik","year":"2018","journal-title":"Future Sci OA"},{"key":"2021122511445281400_onco13721-bib-0028","doi-asserted-by":"crossref","first-page":"208","DOI":"10.4236\/jct.2014.52026","article-title":"Differences in treatment patterns and health care costs among non-Hodgkin's lymphoma and chronic lymphocytic leukemia patients receiving rituximab in the hospital outpatient setting versus the office\/clinic setting","volume":"5","author":"DaCosta","year":"2014","journal-title":"J Cancer Ther"},{"key":"2021122511445281400_onco13721-bib-0029","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.2217\/fon-2018-0267","article-title":"Economic burden of patients with diffuse large B-cell and follicular lymphoma treated in the USA","volume":"14","author":"Morrison","year":"2018","journal-title":"Future Oncol"},{"key":"2021122511445281400_onco13721-bib-0030","volume-title":"Optum. Data Mart User Manual. 2018"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/onco.13721","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/onco.13721","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/5\/e817\/41924131\/oncolo_26_5_e817.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/5\/e817\/41924131\/oncolo_26_5_e817.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T11:45:32Z","timestamp":1640432732000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/26\/5\/e817\/6445630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,15]]},"references-count":30,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,3,15]]},"published-print":{"date-parts":[[2021,5,1]]}},"URL":"https:\/\/doi.org\/10.1002\/onco.13721","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,5,1]]},"published":{"date-parts":[[2021,3,15]]}}}